Myasterix

Biologicalexperimental

Clinical trial activity

2 trials · 4 clinical orgs · 0 marketing orgs

Phase 1
1
Phase 2
1
Phase 3
1
Phase 4
0

Earliest trial started Mar 1, 2016 (NCT02609022)

Timeline

2010s

  1. Jan 1, 2016

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2017

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

  • Unspecified targetImmunity, active

    immunity, active

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • cv-mg01

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT03165435Phase 2/Phase 3 (Phase 3)Jun 23, 2017Aepodia, CuraVac, Leiden University, University of Antwerp
NCT02609022Phase 1/Phase 2 (Phase 2)Mar 1, 2016Aepodia, CuraVac, Leiden University, University of Antwerp
Showing 2 of 2 trials
Page 1 / 1

Organizations

Research & Development (4)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
AepodiaFor profit2022016
CuraVacFor profit2222016
Leiden UniversityAcademic/Hospital2022016
University of AntwerpAcademic/Hospital2022016
4 organizations
Page 1 / 1